Anastasia Katsiampoura, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Diseases | 5 | 2024 | 2781 | 1.360 |
Why?
|
| Atrial Septum | 1 | 2021 | 60 | 0.770 |
Why?
|
| Hypernatremia | 1 | 2018 | 78 | 0.610 |
Why?
|
| Hyponatremia | 1 | 2018 | 279 | 0.520 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2021 | 607 | 0.510 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2023 | 3627 | 0.450 |
Why?
|
| Sodium | 1 | 2018 | 1588 | 0.430 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2015 | 395 | 0.420 |
Why?
|
| Anesthesia | 2 | 2022 | 1595 | 0.320 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3605 | 0.310 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2022 | 1086 | 0.280 |
Why?
|
| Preoperative Care | 1 | 2015 | 2242 | 0.260 |
Why?
|
| Colorectal Neoplasms | 4 | 2019 | 6938 | 0.250 |
Why?
|
| src-Family Kinases | 2 | 2017 | 535 | 0.210 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2024 | 267 | 0.190 |
Why?
|
| Antiemetics | 1 | 2022 | 186 | 0.180 |
Why?
|
| Pandemics | 1 | 2020 | 8656 | 0.180 |
Why?
|
| Punctures | 1 | 2021 | 366 | 0.180 |
Why?
|
| Anesthesia, Conduction | 1 | 2022 | 262 | 0.160 |
Why?
|
| Needles | 1 | 2021 | 451 | 0.160 |
Why?
|
| Algorithms | 1 | 2018 | 14033 | 0.150 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 18255 | 0.150 |
Why?
|
| Fluoroscopy | 1 | 2021 | 947 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2020 | 1835 | 0.130 |
Why?
|
| Interleukin-8 | 1 | 2019 | 696 | 0.130 |
Why?
|
| Thoracic Surgery | 1 | 2022 | 722 | 0.120 |
Why?
|
| Respiratory Insufficiency | 1 | 2022 | 1230 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2022 | 1376 | 0.110 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2023 | 1400 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2023 | 1553 | 0.100 |
Why?
|
| Pneumonia | 1 | 2022 | 2143 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1745 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2019 | 3208 | 0.080 |
Why?
|
| Humans | 17 | 2024 | 761596 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2020 | 3443 | 0.070 |
Why?
|
| Comorbidity | 1 | 2020 | 10508 | 0.060 |
Why?
|
| Critical Illness | 1 | 2018 | 2723 | 0.060 |
Why?
|
| Organoplatinum Compounds | 2 | 2017 | 407 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2018 | 3744 | 0.060 |
Why?
|
| Leucovorin | 2 | 2017 | 643 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 58984 | 0.060 |
Why?
|
| Male | 8 | 2022 | 360846 | 0.050 |
Why?
|
| Surgical Wound Infection | 2 | 2022 | 1529 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2019 | 3816 | 0.050 |
Why?
|
| Female | 8 | 2022 | 392705 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 15266 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 11120 | 0.050 |
Why?
|
| Fluorouracil | 2 | 2017 | 1642 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 5305 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2022 | 5882 | 0.050 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2022 | 128 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 11461 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 11742 | 0.040 |
Why?
|
| Inflammation | 1 | 2019 | 10774 | 0.040 |
Why?
|
| Aged | 3 | 2020 | 169310 | 0.040 |
Why?
|
| Middle Aged | 4 | 2020 | 220921 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 6815 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 36426 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2022 | 1092 | 0.030 |
Why?
|
| Skilled Nursing Facilities | 1 | 2020 | 398 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 4915 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 2022 | 1174 | 0.030 |
Why?
|
| Adult | 5 | 2022 | 221210 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2022 | 1948 | 0.030 |
Why?
|
| Mitral Valve | 1 | 2023 | 1465 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2022 | 1202 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 883 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 59260 | 0.020 |
Why?
|
| ras Proteins | 1 | 2017 | 1054 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 11122 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 23447 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 8554 | 0.020 |
Why?
|
| Echocardiography | 1 | 2023 | 4989 | 0.020 |
Why?
|
| Oxygen | 1 | 2022 | 4227 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2017 | 3606 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 81539 | 0.020 |
Why?
|
| Curriculum | 1 | 2022 | 3743 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 1079 | 0.020 |
Why?
|
| Animals | 2 | 2017 | 168475 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 2057 | 0.020 |
Why?
|
| Length of Stay | 1 | 2020 | 6426 | 0.020 |
Why?
|
| Recurrence | 1 | 2019 | 8466 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2023 | 64685 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2827 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 2645 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2022 | 80647 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 20100 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 2529 | 0.010 |
Why?
|
| Protein Binding | 1 | 2014 | 9353 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 9280 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2022 | 15633 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2022 | 41495 | 0.010 |
Why?
|
| Prognosis | 1 | 2019 | 29629 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 5672 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2022 | 54423 | 0.010 |
Why?
|
| Mutation | 1 | 2017 | 30053 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 13642 | 0.010 |
Why?
|